Prevention of catheter-related deep vein thrombosis with nadroparin in hemato-oncology patients treated with high dose chemotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21969

Enrollment

100

Registered

2006-04-21

Start date

2002-04-10

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical trial.

Interventions

Nadroparin SC 1 dd 2850 E versus placebo 0.3 ml SC during 21 days.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Central venous catheter; 2. Indication for high dose chemotherapy (AML, ALL, MDS-RAEB, MM); 3. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Current anticoagulant therapy; 2. Allergy for contrastmedia; 3. AML-M3 (promyelocytic leukemia); 4. Bleeding tendency; 5. Renal failure.

Design outcomes

Primary

Measure	Time frame
Asymptomatic and symptomatic catheter-related deep vein thrombosis proven by ultrasound or venography.	—

Secondary

Measure	Time frame
1. Catheter-related infections; 2. Bleeding complications.	—

Contacts

Public ContactB.J. Biemond

Academic Medical Center (AMC), Department of Clinical Chemistry, P.O. Box 22660

b.j.biemond@amc.uva.nl+31 (0)20 5667391

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)